Recently, with the increasing number of case reports of the incidental uptake of PSMA in HCC lesions and the IHC confirmation of PSMA expression in the neovasculature of HCC [8,31,32,33], some authors speculated whether PSMA-targeted PET/CT could be useful to evaluate the expression of this antigen by the tumor and to select patients who would benefit from a tailored PRLT after the failure of conventional treatments. Here, FOLH1 is linked to hepatocellular carcinoma.